Market closed
Shattuck Labs/$STTK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Ticker
$STTK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
75
Website
Shattuck Labs Metrics
BasicAdvanced
$82M
-
-$1.52
1.86
-
Price and volume
Market cap
$82M
Beta
1.86
52-week high
$11.76
52-week low
$0.94
Average daily volume
157K
Financial strength
Current ratio
7.962
Quick ratio
7.262
Long term debt to equity
2.839
Total debt to equity
3.743
Management effectiveness
Return on assets (TTM)
-41.07%
Return on equity (TTM)
-71.09%
Valuation
Price to revenue (TTM)
13.044
Price to book
0.85
Price to tangible book (TTM)
0.85
Price to free cash flow (TTM)
-1.34
Growth
Revenue change (TTM)
382.75%
Earnings per share change (TTM)
-31.89%
3-year revenue growth (CAGR)
71.26%
3-year earnings per share growth (CAGR)
-1.02%
What the Analysts think about Shattuck Labs
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Shattuck Labs stock.
Shattuck Labs Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Shattuck Labs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Shattuck Labs News
AllArticlesVideos
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewsWire·6 days ago
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewsWire·2 weeks ago
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Shattuck Labs stock?
Shattuck Labs (STTK) has a market cap of $82M as of February 26, 2025.
What is the P/E ratio for Shattuck Labs stock?
The price to earnings (P/E) ratio for Shattuck Labs (STTK) stock is 0 as of February 26, 2025.
Does Shattuck Labs stock pay dividends?
No, Shattuck Labs (STTK) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Shattuck Labs dividend payment date?
Shattuck Labs (STTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Shattuck Labs?
Shattuck Labs (STTK) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.